Key result
A 40-year-old pregnant woman with combined factor V Leiden mutation and antithrombin III deficiency developed massive deep vein thrombosis and cerebral venous sinus thrombosis despite therapeutic enoxaparin.
Why the study?
Women with combined inherited thrombophilia are at high risk of thrombotic events during pregnancy, and thrombotic events can still occur despite low-molecular-weight heparin anticoagulation.
Does therapeutic enoxaparin prevent massive deep vein thrombosis and cerebral venous sinus thrombosis in a pregnant patient with combined factor V Leiden mutation and antithrombin III deficiency?
Case Report (n=1)
Does therapeutic enoxaparin prevent massive deep vein thrombosis and cerebral venous sinus thrombosis in a pregnant patient with combined factor V Leiden mutation and antithrombin III deficiency?
Therapeutic doses of enoxaparin may fail to prevent severe thrombotic events in pregnant women with combined inherited thrombophilia such as factor V Leiden and antithrombin III deficiency.
Answers are grounded in this paper and cite their sources.
This case suggests possible enoxaparin failure in combined thrombophilia pregnancy; leaves open optimal regimens and need for prospective data.
Women with combined inherited thrombophilia are at high risk of developing thrombotic events, especially when they are pregnant. Low-molecular-weight (LMW) heparins are the preferable agents for anticoagulation during pregnancy. Despite the fact that they have been proven to be effective in the treatment and prevention of venous thromboembolism, thrombotic events can still happen. Here, we report a case of a 40-year-old white pregnant woman with combined factor V Leiden mutation and antithrombin III deficiency who developed massive deep vein thrombosis and cerebral venous sinus thrombosis despite being on therapeutic doses of enoxaparin.
No takes yet. Share an insight, caveat, or question.
Al-Dubai et al. (2021) conducted a case report in Combined factor V Leiden mutation and antithrombin III deficiency in pregnancy (n=1). Enoxaparin was evaluated on Massive deep vein thrombosis and cerebral venous sinus thrombosis. A 40-year-old pregnant woman with combined factor V Leiden mutation and antithrombin III deficiency developed massive deep vein thrombosis and cerebral venous sinus thrombosis despite therapeutic enoxaparin.
Synapse has enriched 10 related papers. Consider them for comparative context: